Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400004 · ClinicalTrials.gov registry record · Phase 3
Lumason® Infusion vs. Bolus Administrations
A Phase 3 study of Heart Diseases, sponsored by Bracco Diagnostics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 106
- Enrollment target
- 6
- Study locations
NCT06400004 is a Phase 3 study of Heart Diseases that is actively recruiting participants, run by Bracco Diagnostics. The registered enrollment target is 106 participants, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06400004, a Phase 3 study of Heart Diseases, is actively recruiting participants, sponsored by Bracco Diagnostics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 106 participants
- Enrollment target
- 6
- Study locations
Study Summary
A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary endpoints).
Conditions Studied
Interventions
- DRUG Lumason
- DRUG Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
Study Locations (6)
Texas
- University of Texas Medical Branch - Galveston
- Vital Heart and Vein - Humble
California
- Interventional Cardiology Medical Group - West Hills
Georgia
- Piedmont Heart Institute - Atlanta
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Oregon
- Oregon Health and Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06400004
The ClinicalTrials.gov registry entry for NCT06400004 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (98% lower). The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Diseases appearing as the primary indexed condition, and to 2 interventions - of which Lumason is the first listed.
NCT06400004 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06400004 about?
NCT06400004 is a clinical study titled "Lumason® Infusion vs. Bolus Administrations". A phase III study designed as a randomized, within-patient comparison of continuous infusion of diluted Lumason® versus the bolus administration of undiluted Lumason® for degree of LVO and assessment of LV EBD (co-primary endpoints).
What is the current status of trial NCT06400004?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 106 participants. The study started on 2024-07-10. Estimated completion is 2026-12-31.
What conditions does trial NCT06400004 study?
This clinical trial studies the following conditions: Heart Diseases.
What interventions are being tested in trial NCT06400004?
The interventions under investigation include: Lumason (DRUG), Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON] (DRUG).
Who is sponsoring clinical trial NCT06400004?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400004 being conducted?
This trial has 6 study locations across California, Georgia, Massachusetts, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Comparison of Hematocrit Levels in Infant Heart Surgery
COMPLETED · Phase 3
-
Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease
COMPLETED · Phase 3
-
Occluded Artery Trial (OAT)
COMPLETED · Phase 3
-
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
COMPLETED · Phase 3
-
Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.